Etiket: lenacapavir
An antiretroviral developed by Gilead based on the molecule lenacapavir could be a game-changer against AIDS
A treatment considered very promising against AIDS, which costs about $40,000 per person each year, could fall to around $40 in a generic version, according to an estimate unveiled Tuesday…